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Introduction
   Traditionally, most drugs were composed of 
organically synthesized compounds with relatively 
low molecular weights which were administered 
orally. These drugs have a long history of research 
and development and a number of them have become 
“blockbusters,” with sales of over 100 billion yen. 
These small molecule drugs are effective in treating 
certain types of diseases: however, they are not 
as effective in treating others. Many biomedical 
researchers in the pharmaceutical industry as well as 
in universities and public research institutions have 
been making great efforts to meet these unmet medical 
needs. Within this scope, researchers have come up 
with various candidates including and beyond small 
molecule compounds, and evaluated their efficacy and 
safety. With the development of recombinant DNA 
technology in the 1980s, protein drugs became one 
of the major successes. Protein drugs are artificially 
mass synthesized protein molecules with important 
and innate biological functions. Since protein drugs 
cannot be administered orally due to their high 
molecular weight, they are usually administered 
via injection or infusion. Well known examples are 
insulin for diabetes treatment, erythropoietin for 
anemia treatment, and several interferons for viral 
hepatitis treatment, all of which, to date, have been 
the main therapeutic agents for each disease category. 
In the 1990s, rituximab (Rituxan®) and trastuzumab 
(Herceptin®), anti-cancer drugs made with antibodies 
that make use of human immune functions, were 
launched and were soon widely used due to their high 
efficacy and safety. 
   Antibody drugs received much attention and became 
active targets for research and development in the 
1980s. However, most ended unsuccessfully, due in 
part to antigenecity problems which will be mentioned 
later, and many companies left the field. Subsequent 
development of antibody engineering technology 
1 enabled the development of effective drugs. Since 
antibody drugs are proteins, they, like protein drugs, 
are also usually administered through injection or 
infusion. 
   In this report, I will give an overview of antibodies 
and antibody drugs and discuss their issues and 
possible solutions.
What are antibody drugs?
   Simply stated, antibody drugs are drugs that use the 
characteristics of the strict recognition specificity of 
antibodies to antigens. 
   Hence, I will describe what antibodies are and the 
characteristics which have brought them to the current 
spot light. 
2-1 Antibodies
   Antibodies are glycoproteins produced in the body 
to attack and eliminate bacteria and viruses upon their 
entry to the body, and constitute a part of the immune 
system at the core of the body’s biological defense. As 
chemical agents, they are called immunoglobulin and 
abbreviated Ig. They are produced by B cells, a type of 
lymphocyte, which is an immune cell. Each antibody 
binds to a specific agent (antigen), and become a 
“marker” for elimination by immune competent 
cells, or disrupts (neutralizes) the activity of antigen 
molecules in the body. 
  Figure 1 shows a diagram of an antibody’s molecular 
structure. The basic structure consists of 2 heavy 
chains linked to 2 light chains, and is usually 
presented as Y shape. 
   The vertical part of the Y is called Fc region 
(Fragment, crystallizable), the region recognized by 
immune competent cells. Immune competent cells are 
known to attack cells through the recognition of the 
Fc region of bound antibodies. (Antibody-dependent 
cellular cytotoxicity [ADCC]) and this is an important 
mechanism of antibody drugs against cancer for later 
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discussion. 
  On the other hand, the upper arm region of the Y is 
called the Fab region (fragment, antigen binding), at 
the tip of which is where antibodies bind to antigens. 
The apex of the Fab region is called the variable region 
due to the variety in its amino acid sequence to bind 
various antigens. The rest of the region has a relatively 
steady amino acid sequence and is thus called the 
constant region. 
2-2 Monoclonal Antibodies 
   To produce antibodies for a certain protein molecule, 
the protein is usually injected into animals such as 
mice, and the antibodies are subsequently collected 
from their serum. Although one B cell produces only 
one type of antibody, since different B cells produce 
divergent antibodies against one protein molecule, 
the serum contains various antibody molecules with 
different specificities (polyclonal antibodies). In 1975, 
Köhler and Milstein invented a method to make 
antibody-producing cells with autonomic proliferation 
abilities (hybridoma) by fusing individual antibody-
producing cells with myeloma cells. Monospecific 
antibodies produced by a single cell clone with this 
method are called monoclonal antibodies. This method 
enabled mass production of monospecific antibodies, 
providing a powerful research tool for subsequent 
drug development as well as basic research (together 
with Jerne, Köhler and Milstein were awarded the 
Nobel Prize in Physiology or Medicine in 1984).
   In the 1980s, with expectations for monoclonal 
antibodies growing greater, various treatments were 
tested, including their use as “missile therapy” into 
which toxins or anti-cancer compounds could be 
loaded for attacks on the target. However, none of 
these tests ended successfully. The main reason is 
believed to be that the antibodies used in these trials 
were derived from mice. Since the human immune 
system recognizes these murine antibodies as foreign 
antigens, this elicits antibodies which render them 
inactive, and they are eliminated from the system. 
   Subsequently, antibody engineering technology 
was developed to produce chimeric antibodies 
which possess a murine variable region and a 
human constant region; humanized antibodies with 
all human fragments except for their murine CDR 
(complementarity-determining region), a region that 
directly binds to antigens; and fully human antibodies 
in which all regions are derived from human 
(Figure 2). In addition, the establishment of cell 
culture technology which enabled the production of 
monoclonal antibodies by introducing and expressing 
the antibody genes into cells such as CHO (Chinese 
hamster ovary) cells rather than using the whole 
body of mice set the foundation for practical drug 
production, thus leading to the practical application of 
The Diversity of Antibodies
   Our bodies can synthesize antibodies that bind to a large number of antigens. How this large variety 
of antibody molecules are synthesized from such a limited number of genes had long been a great 
immunological mystery. This mystery was solved by Dr. Susumu Tonegawa who was later awarded 
Nobel Prize for his achievement. His findings revealed that one of the various segments located on 
each of the V, D, and J regions of heavy chain gene, for example, are selected randomly and attached 
together to form genes of the variable region, and these combinations contributed to their variety.[1] On 
the other hand, there are two known phenomena promoting the maturation of antibody genes; one is 
called “class switch,” and is a change in the sequence of constant region, and the other one is “somatic 
hypermutation,” which generates further diversity of the variable region. Research that contributed to 
finding these phenomena was led by Dr. Tasuku Honjo.[2] As shown here, Japanese researchers have 
made great contributions to the basic research of antibodies. 
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Prepared by the STFC based on http://chugai-pharm.co.jp/thml/meeting/pdf/060922.
pdf “Development and Future of Antibody Drugs” by Masayuki Tsuchiya at Chugai 
Pharmaceutical Co., Ltd.
Figure 2 : Mouse Antibody, Chimeric Antibody, Humanized Antibody, and Human 
Antibody
antibody drugs. 
2-3 General Mechanisms of Drug Efficacy
   As mentioned in 2-1, antibodies have various 
effects in the body. Binding inhibition and antibody-
dependent cellular cytotoxicity (ADCC) are important 
mechanisms of antibody drugs.
(1) Binding Inhibition
   Binding inhibition refers to the action of inhibiting 
the binding between receptors and the compounds 
(ligands) that bind to them and trigger certain 
processes. This is achieved by binding to the receptors 
and inhibiting the ligand’s binding or vice versa. 
These drugs have the beneficial effect of blocking 
intracellular signal transduction. Examples of 
clinically used drugs include antibody drugs which 
induce binding inhibition between proliferation 
factors and cancerous cells, and ones which inhibit 
Prepared by the STFC
Figure 3 : Mechanisms of Antibody Drug Effectiveness
the activation of immunomodulating substances. 
Although antibodies against bacteria and viruses do 
not entail receptor/ligand binding, they work in the 
same way by inhibiting the binding and invasion of 
these pathogens to the cells. 
(2) Antibody-Dependent Cellular Cytotoxicity and 
Complement-Dependent Cellular Cytotoxicity
   Natural killer cells (NK cells) and monocytes are 
the main cells to attack and eliminate cancerous and 
virally infected cells. These cells have Fc receptors 
which recognize the Fc region of antibodies and kill 
the cells or pathogens to which the antibodies are 
bound. This is called antibody-dependent cellular 
cytotoxicity (ADCC). On the other hand, complement-
dependent cellular cytotoxicity (CDCC) refers to a 
similar cytopathic function by complement molecules. 
Some antibody medications already used as anti-
cancer medications have ADCC and CDCC as their 
Figure 2 Mouse Antibody, Chimeric Antibody, Humanized Antibody, and Human Antibody
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main effective mechanisms.
(3) Others
   Target cells can be killed by anti-cancer agents or by 
radionuclides bound to antibodies targeted these cells. 
These agents are expected to act more powerfully 
than the immune system, and some are already on the 
market. 
2-4 Characteristics of Antibody Medicine
(i) High Specificity
   Antibodies bind only to the target antigens and do 
not bind to anything else. This means that antibody 
drugs have high specificity, which brings about the 
target effect without causing unexpected side effects. 
This high specificity is used not only in therapeutics, 
but also in diagnostic drugs. In addition, this is an 
important tool for detecting and identifying target 
molecules and the cells that produce these targets in 
biomedical research. 
(ii) High Stability in the Body
   Antibodies are molecules that by nature exist stably 
in the blood. Antibody drugs remain stable in the 
blood long after administration and maintain their 
effectiveness. Their normal half-life in the blood is 
several days, and standard administration is usually 
once a week to once every few weeks.
 
(iii) Low Toxicity
   Since these are molecules that exist naturally in the 
body, the possibility that they will exhibit toxicity is 
low. 
(iv) Relatively Easy to Obtain Best Antibodies
   Once antibodies with good specificity and 
binding activity have been obtained, further work 
such as complex modifications of the structure is 
not necessary, as is the case with small molecular 
compounds. 
(v) High Commonality in Production and 
Purification
   Every type of antibody shares an almost identical 
basic structure and similar physicochemical properties 
with other types. Therefore, once production and 
purification process are established with one type of 
antibody, very similar methods can be used to produce 
and purify other types. Currently, the international 
standard method uses CHO cells as the host. 
Therefore, as long as this production system is used, it 
will be relatively easy to produce various antibodies as 
well as to do contract manufacturing. 
Current Status of Antibody Drugs
   Here I will talk about sales in antibody drugs and 
about major antibodies including those still under 
development.
3-1 Sales of Antibody Drugs
  Table 1 shows the sales numbers of 2008’s top 30 
drugs in the world. Along with small molecule drugs 
for chronic diseases such as hyperlipidemia and 
hypertension, there were 5 antibody drugs in the top 
15. Rituxan®, ranked 4th, and Remicade®, ranked 
6th, each took in over US$6 billion in annual sales 
worldwide, while Avastin®, ranked 10th, Herceptin®, 
ranked 11th, and Humira®, ranked 15th, each had sales 
of over US$4 billion, becoming “blockbuster” drugs. 
All of these are double-digit increases over the sales 
of the previous year. Some even showed an over 10% 
sales increase compared to the previous year nearly 10 
years after having come onto the market. The rate of 
increase was especially great for those drugs recently 
introduced to the market, for example, Humira®, 
ranked 15th, showed a 48% increase. Indications of 
these high-ranking drugs are rheumatoid arthritis 
and certain types of cancer. Their wide use despite 
the high cost suggests antibody medications show 
a greater effectiveness of treatment against these 
diseases than traditional small molecule drugs, as well 
as having fewer side effects. 
3-2 Main Fields of Indication and Therapeutic 
Mechanisms of Antibody Medication
   Table 2 shows major antibodies either on the market 
or in the process of development (Phase 3 of clinical 
trials or later) in each field of diseases. Here, I will 
introduce representative antibodies as well as other 
noteworthy ones. 
(1) Antibody Drugs for Rheumatoid Arthritis[3]
   The main target of antibody drugs is inflammatory 
cytokine, TNF-α, forming a huge market. Antibody 
drugs are reputed to be more effective than the 
traditional, standard treatments. In addition, since 
TNF-α plays a central role in inflammatory response, 
3
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these antibody drugs are often indicated for other 
inflammatory diseases such as Crohn’s disease. 
   Well known antibody drugs targeting TNF-α are 
chimeric antibody infliximab (Remicade®), and the 
fully human antibody adalimumab (Humira®). Enbrel® 
(etanercept), though not exactly a typical antibody 
drug, binds TNF-α at its TNF-α receptor region and 
eliminates it. The total annual sales of these three 
Brands Product Name Indications Companies 2008 sales (million $ U.S.)
year-on-
year rate
2007 sales 
(million $ U.S.)
1 Lipitor Atorvastatin Hyperlipidemia/statin Pfizer and Astellas 13,476 -2% 13,682
2 Plavix Clopidrogel Antiplatelet medication Sanofi-Aventis and Bristol-Myers Squibb 9,291 12% 8,325
3 Advair/seretide
Fluticasone 
Salmetrol Asthma medication 
GlaxoSmithKline and 
Almiral 7,737 9% 7,082
4 Rituxan Rituximab Non Hodgkin's Lymphoma Biogen Idec and Roche 6,739 16% 5,826
5 Embrel Etanercept Rheumatoid arthritis/Psoriasis Amgen, Wyeth and Takeda 6,447 18% 5,442
6 Remicade Infliximab Rheumatoid arthritis/Crohn's disease
J&J (Centcore), Schering-
Plough and Mitsubishi 
Tanabe
6,230 19% 5,230
7 Diovan Valsartan Antihypertensive medication/ARB Novartis and Ipsen 6,227 22% 5,091
8 Nexium Esomaprazole Anti-Ulcer/PPI AstraZeneca 5,200 -2% 5,216
9 Epogen/Procrit Epoetin alfa
Anemia associated with 
renal failure Amgen, J&J and Kirin 5,116 -11% 5,746
10 Avastin Bevacizumab Anti-colon/breast cancer medication Genentech and Roche 4,933 37% 3,648
11 Herceptin Trastuzumab Anti-HER2-breast cancer
Genentech, Roche and 
Chugai 4,824 12% 4,311
12 Zyprexa Olanzapine Schizophrenia medication Eli Lilly 4,696 -1% 4,761
13 Seroquel Quetiapine fumarate
Schizophrenia 
medication AstraZeneca and Astellas 4,656 11% 4,198
14 Singulair Montelukast Asthma and bronchial asthma medication Merck and Kyorin 4,582 3% 4,436
15 Humira Adalimumab Rheumatoid arthritis/Psoriasis Abbott and Eisai 4,539 48% 3,064
16 Crestor Rosuvastatin Hyperlipidemia/statin Shionogi and AstraZeneca 4,103 30% 3,154
17 Actos Pioglitazone Type 2 Diabetes Takeda and Lilly 4,063 4% 3,901
18 Effexor XR Venlafaxine Antidepressant/SSRI Wyeth and Almiral 3,994 3% 3,868
19 Lovenox Enoxaparin Anticoagulant Sanofi Aventis 3,860 11% 3,847
20 Lexapro/Cipralex Escitalopram Antidepressant/SSRI Antidepressant/SSRI 3,845 4% 3,698
21 Blopress/Atacand Candesartan
Antihypertensive 
medication/ARB
Antihypertensive 
medication/ARB 3,769 13% 3,327
22 Cymbalta Duloxetine Antidepressant/SSRI Antidepressant/SSRI 3,737 68% 2,231
23 Gleevec Imatinib Anticancer/chronic myelogenous leukemia
Anticancer/chronic 
myelogenous leukemia 3,670 15% 3,050
24 Cozaar/Nu-lotan Losartan
Antihypertensive 
medication/ARB
Antihypertensive 
medication/ARB 3,558 6% 3,350
25 Lantus Insulin glargine Insulin Analogue Insulin Analogue 3,454 21% 2,991
26 Aricept Donepezil Alzheimer's disease Alzheimer's disease 3,438 15% 2,994
27 Risperdal Risperidone Schizophrenia Schizophrenia 3,435 -24% 4,697
28 Aranesp/Nesp Darbepoetin Renal Anemia Renal Anemia 3,362 -12% 3,614
29 Neulasta Pegfilgrastim Neutropenia /G-CSF Neutropenia /G-CSF 3,318 11% 3,000
30 Abilify Aripiprazole Schizophrenia Schizophrenia 3,312 30% 2,554
drugs exceed US$17 billion. In addition, certolizumab 
pegol has only the antigen binding domain (Fab) of 
anti-TNF-α antibody to which synthetic polymer 
polyethylene glycol (PEG) is attached.  PEG increases 
stability in the blood and reduces immunogenicity 
of Fab, which binds to and neutralizes TNF-α.[5] 
However, since TNF-α is an important molecule in the 
immune system, special attention must be paid to the 
Prepared by the STFC based on Major Drug Sales Ranking 2008, 
Uto Brain Co., Ltd. News Release, http://www.utobrain.co.jp/
news-release/2009/0730/index.shtml
Table 1 : World Wide Drug Sales Ranking 2008
Note: Antibody drugs are shown in bold with boxes. 
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possibility of infectious diseases arising.
   On a related note, tocilizumab (Actemra®) is the 
first and only domestically developed antibody drug, 
created through the collaborative research of Osaka 
University and Chugai Pharmaceutical Co., Ltd. It 
also targets inflammatory cytokine, IL-6 receptor, and 
works by inhibiting the binding of IL-6.[6]
(2) Antibody Drugs for Hematologic Cancers
   As shown in Table 2, many antibodies used to treat 
hematologic cancers which target CD20. Many of 
these are used for treating well known hematologic 
cancers such as malignant lymphoma and non-
Hodgkin’s lymphomas. CD20 is a differentiation 
Product Name Brands Target Molecules 
Autoimmune Diseases
Rheumatoid Arthritis
infliximab Remicade TNF-α
adalimumab Humira TNF-α
tocilizumab Actemra IL-6 recetor
certolizumab pegol Cimzia TNF-α
[golimumab] Simponi TNF-α
[ofatumumab] Arzerra CD20
[ocrelizumab] CD20
Multiple Sclerosis
natalizmab Tysabri α4 integrin
[alematuzumab] Campath CD52
Systemic Lupus Erythematosus
[epratuzumab] LymphoCide CD22
[belimumab] LymphoStat-B BLyS
C a n c e r  a n d  R e l a t e d 
Diseases
Hematologic Cancers
rituximab Rituxan CD20
gemtuzumab Mylotarg CD33
alematuzumab Campath CD52
iblitumomab tiuxetan Zevalin CD20
[bevacizumab] Bexxar CD20
[galiximab] CD80
[zanolimumab] HuMax-CD4 CD4
[ofatumumab] Arzerra CD20
Breast Cancer
trastuzumab Herceptin HER2
bevacizumab Avastin VEGF
[pertuzumab] Omnitarg HER2
Colon Cancer
bevacizumab Avastin VEGF
cetuximab Erbitux EGF receptor
panitumumab Vectibix EGF receptor
Cancers of the Head and Neck
cetuximab Erbitux EGF receptor
[panitumumab] Vectibix EGF receptor
Others
[cetuximab] Erbitux EGF receptor
[denosumab] Prolia RANKL
[trastuzumab] Herceptin HER2
[ipilimumab] MDX-010 CTLA-4
Cardiovascular Diseases Myocardial Infarction abciximab Reopro IIb/IIIa
Infectious Diseases RSV Infections
palivizumab Synagis RSV F protein
[motavizumab] Numax RSV F protein
Neural Diseases Alzheimer's Disease
[bapineuzumab] Aβ
[solanezumab] Aβ
Others
Maculopathy ranibizumab Lucentis VEGF
Asthma omalizumab Xolair IgE
Osteoporosis [dinosmab] Prolia RANKL
Prepared by the STFC based on Reference[4]
Table 2 : Main Fields of Diseases, Antibody Drugs on Sale or Being Developed, 
and Their Target Molecules (Main Antibody Drugs on Sale and Under 
Development) 
Bold letters indicate drugs already on the market also in 
Japan. Brackets indicate the drugs that are currently under 
development (Phase 3 or later phase of Clinical Trials). 
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antigen of B cells, however, much remains unclear 
about its function. 
   Rituximab (Rituxan®)[7] is a chimeric antibody drug 
which targets human CD20, and its main mechanisms 
of action are ADCC and CDCC. It is used alone or 
in combination with traditional chemotherapeutic 
drugs. It is a very effective drug which is said to 
have greatly changed traditional treatment. However, 
it's also true that there are noneffective cases and 
relapsed cases. The drugs developed to be more 
effective are ibritumomab tiuxetan (Zevalin®) and 
tositumomab (Bexxar®), which are antibodies bound 
with radionuclides. Both, like rituximab, target 
CD20 and damage the cancerous cells with radiation. 
Ibritumomab tiuxetan came onto the Japanese 
market in 2008, and it is one of the most expensive 
medications, costing over 5 million yen when used in 
conjunction with other medications.[8] Clinical trials in 
the U.S. showed ibritumomab tiuxetan to be effective 
in 80% of the cases, surpassing rituximab’s 56%, 
and more over, it was effective in 74% of rituximab-
resistant cases.[9] 
(3) Antibody Drugs for Breast Cancer 
   Trastuzumab (Herceptin®) is a drug for breast cancer 
(metastatic breast cancer which overexpresses HER2). 
By binding to HER2, a cancer gene product and 
member of EGF (epidermal growth factor) receptor 
family, it blocks growth signals as well as killing 
cancerous cells through ADCC. A clinical trial abroad 
has reported that a combination of traditional anti-
cancer drugs and trastuzumab completely eliminated 
cancer cells in 70% of patients. Pertuzumab 
(Omnitarg®) is another antibody that binds to HER2, 
though the binding site is different from trastuzumab. 
Pertuzumab also has a different mechanism of action, 
as it inhibits the dimerization of the EGF receptors, 
which is the way the EGF receptor family transmits 
signals. The use of pertuzumab in combination with 
trastuzumab increases sensitivity in trastuzumab-
resistant breast cancer patients.[10] 
(4) Antibodies Drugs for Colon Cancer Treatment
  Bevacizumab (Avastin®) is a humanized antibody 
that binds and inhibits vascular endothelial growth 
factor (VEGF). VEGF is a factor involved in 
angiogenesis, and inhibiting this factor cuts the 
nutrient supply and kills cancerous cells. Usually, it 
is used in combination with traditional chemotherapy 
medication. As this mechanism of action is believed 
to be very effective for many types of cancers, its 
use for non-small cell lung carcinoma and HER2 
negative breast cancer has been approved in the U.S. 
In addition, clinical trials are underway for many 
cancers, including ovarian cancer, prostate cancer, and 
kidney cancer and so on. 
   Panitumumab (Vectibix®) and cetuximab (Erbitux®) 
target EGF receptors. They suppress cancer growth by 
blocking the growth signal of the EGF. Panitumumab 
is a fully human antibody and is awaiting approval for 
use in Japan, while cetuximab is a chimeric antibody 
that has already been launched in Japan. 
(5) Preventive Medicine for RSV Infection[11]
   RSV (respiratory syncytial virus) infects the 
respiratory organs of infants triggering bronchitis, and 
though normally patients recover within a week or 
two, the infection can easily get more severe in infants 
with congenital disorders in their cardiovascular or 
respiratory system. There is, however, no effective 
drug to treat RSV infections at the present time. 
Palivizumab (Synagis®) is a humanized antibody that 
binds to the F protein of RSV, and is administered 
to infants with above mentioned disorders as a 
preventative medicine. Motavizumab (Numax®) is 
also a humanized antibody which binds to RSV, and it 
is currently in the process of development. 
(6) Antibody Drugs for Alzheimer’s Disease
  Bapineuzumab and Solanezumab[12] are humanized 
antibodies which bind to β amyloid (Aβ) which 
is believed to be one of the pathogenic factors 
in Alzheimer’s disease. Although some of their 
mechanisms are unclear, since there are no drugs 
on the market to slow the progression of the disease, 
expectations for them are high. It is currently 
undergoing phase 2 of clinical trials. 
(7) Antibody Drugs for Osteoporosis 
  Denosumab (Prolia)[13] is a fully human antibody 
that binds to the molecule required for osteoclast 
differentiation called RANKL. Inhibition of RANKL 
function reduces the activity of the osteoclasts, 
and bone mass reduction is suppressed. Though 
osteoporosis is more common in post-menopausal 
women, since patients receiving hormone treatment 
to treat prostate cancer and breast cancer tend also 
to have bone mass loss, it is awaiting approval as a 
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preventative and also as a treatment for them. 
Approaches to Solving the Issues 
of Antibody Drugs
(1) Reducing the High Costs 
   One of the biggest problems concerning antibody 
drugs is that they are extremely expensive compared 
to other drugs. For example, for postoperative relapse 
prevention, traditional chemotherapy costs around 
500 to 600 thousand yen whereas trastuzumab 
(Herceptin®) costs over 3 million yen.[14] Since these 
medications are often used in combination, the 
medical bill can easily become even more expensive. 
   Small molecule drugs are inexpensive because 
they are produced by organic synthesis with 
relatively inexpensive materials in a relatively simple 
process. On the other hand, since antibody drugs are 
produced in animal cell culture, expensive culture 
media and equipment are necessary. Additionally, 
since antibodies have high molecular weight and 
complex structures with sugar chains added to 
them, purification and standardization analysis are 
complicated.
   One of the approaches to reduce production costs is 
to use a cheaper host than cultured cells. Currently, 
production using E. coli, yeast, insects, plants, and 
chickens are being evaluated. E. coli can provide a 
production system at a lower cost and has a history of 
being used in the production of other protein drugs. 
However, since E. coli is very distant from a mammal, 
there are various differences. Though production 
of proteins with relatively low molecular weights is 
possible, it is difficult to produce human antibodies 
which are complex tetramers with molecular weights 
of over 150 thousand. The common problem among 
all of the above mentioned organisms is that the sugar 
chains attached to antibody molecules are specific 
to humans. Since sugar chains are believed to make 
antibodies stable in the blood and act as recognition 
markers for immunocytes, the lack of these sugar 
chains or addition of structurally distinct sugar chains 
may disrupt the stability of their long-term therapeutic 
effectiveness or the effect of drugs mediated by 
the immune system. However, since we have been 
making great achievements in sugar chain engineering 
in Japan, many expectations are being placed upon 
further development. 
   Now, this discussion has had as its premise antibody 
drugs with complete structure for treating cancers; 
however, in the case of neutralizing antibody, not all 
the structures are required for their drug efficacy.  As 
mentioned in 3-2 (1), certolizumab pegol (Cimzia®) 
is a drug with polyethylene glycol (PEG), a synthetic 
polymer, bound to Fab, its antigen binding region. 
Since Fab alone is a relatively small molecule, it can 
be produced with E.coli to reduce the cost.[5] 
   Another reason for the high cost of antibody drugs is 
that they are administered at much higher doses than 
traditional protein drugs. Therefore, another approach 
is improving their efficacy so that the dosage can be 
reduced. Since this approach would not only reduce 
costs, but also closely correlate to improvement in 
the drugs’ effectiveness, I will discuss this further in 
Highly Notable Technologies section (5-2). 
(2) Searching for New Target Molecules 
   Antibodies are defined by the antigens they 
recognize. Therefore, finding an appropriate target 
molecule is a great challenge, and a common 
challenge shared in any field of drug research. 
Accordingly, disease-causing and regulator molecules 
for biological functions are actively being searched for 
and functionally analyzed in the field of biomedical 
research. 
   To obtain anticancer antibodies, any molecules 
specifically expressed in cancer cells with or without 
important biological functions might be targets. These 
molecules are somewhat like cellular markers or 
differentiation antigens, have little effect on cellular 
function after antibody binding, however, antibodies 
may kill the cell through ADCC as mentioned in 2-3 
(2). Since this kind of molecules can be searched for 
by specificity or quantity of expression, it is relatively 
easily to screen using DNA chips, and extensive work 
has been done to find candidate targets. However, few 
antibodies developed to date recognize only marker 
molecules. Rituximab (Rituxan®) is an exception as 
its target molecule CD20 is an antigen only expressed 
in B cells and its function is not still clearly known. 
(3) Production of Hard-to-Produce Antibodies
   Since antibody drugs target extracellular molecules, 
secreted proteins such as regulatory factors and 
receptors can be targets as well. In particular, 
antibodies that target the extracellular domain of 
molecules which pass through the cell membrane 
multiple times (multipass transmembrane proteins), 
4
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such as some types of receptors and transporters, 
are known to be difficult to produce with standard 
immunological methods using animals such as 
mice. It is considered that antibodies cannot be 
produced through immunization with imperfect 
molecules because of the difficulty in synthesis and 
purification, and even in immunization with the 
cells themselves that express these molecules, there 
are problems such as insufficient expression, small 
size of the extracellular domain, and a similar amino 
acid sequence to that of mice. Because of this, only 
a handful of antibodies have been produced for such 
complex membrane proteins to date. 
   Multipass transmembrane proteins include many 
important traditional drug targets such as receptors 
and channels. Seven transmembrane receptors 
(GPCRs) are well known examples. Therefore, 
antibodies acting on these molecules are potentially 
pharmaceutically effective. Moreover, even if their 
function is unknown or unimportant, these might 
be the target for antibodies if they are expressed 
specifically in cancer cells. Therefore, if we can 
efficiently produce antibodies which have not been 
successfully produced to date for those molecules, 
therapeutic targets will potentially expand greatly. To 
face these challenges, the ways that the expression 
method of immunizing antigens and methods for 
producing antibodies without using animals are being 
evaluated, both of which will be mentioned later in 
Highly Notable Technologies (5-2). 
R e c e n t  R e s e a r c h  a n d 
Development in Technology 
Related to Antibodies
   All drug research and development, including that 
for antibody drugs, are closely associated with basic 
research in biology and medicine. Basic research 
often brings discoveries on causal molecules of 
certain diseases or molecules which are influenced 
to pathological conditions, as well as bringing a 
further understanding of pathology. These newly 
found molecules have potential as drug targets, and 
knowledge of pathology is extremely important for 
directing drug research and development. In addition, 
chemical compounds and antibodies that are the 
basis for the drugs can be useful tools in biomedical 
research. In more than a few cases, target molecules 
and antibody engineering technology for antibody 
drugs have been discovered through the basic 
research conducted in universities and public research 
institutions. In particular, publicly funded research 
projects are being called upon to direct the progress 
of a wide range of basic research and to lead the 
development of new technology. Here I will introduce 
the topics of public research projects in Japan and 
noteworthy pieces of research. 
5-1 Major Public Research Projects
   Antibody drug research and development is 
conducted mainly in the private sector, such as 
by pharmaceutical companies. The importance of 
the continuous basic research being carried out in 
universities has already been mentioned, and here 
I will focus on the major projects which received 
intensive funding in each time period. 
5-1-1 The Search for New Target Molecules
   Many research projects have been conducted to 
find useful genes and to analyze their functions. 
Finding new targets in fields other than antibody drug 
research, such as in the search for classic drug targets 
and in the functional analysis of disease genes, can 
directly lead to antibody targets. Here I will introduce 
relatively large scale projects. 
(i) Human Full-Length cDNA Project (FL Project)[15]
Period: 1996~2001
Support: The Ministry of Economy, Trade and 
Industry
  This was a joint research project with involvement 
by both the public and private sectors, with the 
participation of the University of Tokyo’s Institute 
of Medical Science, the Helix Research Institute, 
the Kazusa DNA Research Institute, and over 
10 private companies, in which novel full-length 
human cDNAs were collected and their sequence 
information was compiled into a cDNA database. 
Annotations were added to collected information 
on cDNAs in an international collaborative project 
called H-Invitational, and made into a database now 
used all over the world. This set of approximately 
30 thousand of full-length cDNAs has provided 
important research materials, and is included as a 
research source in the Millennium Genome Project 
introduced below. 
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(ii) Genox Research Institute Inc. (private-public joint 
venture)[16]
Period: 1996~2002
Support: The Ministry of Health, Labor and Welfare
  Research projects were undertaken, co-funded 
by the Organization for Pharmaceutical Safety and 
Research under the Ministry of Health, Labor and 
Welfare (at the time), and 8 other private companies, 
which conducted disease specific gene extraction 
and functional analysis on atopy and allergic 
diseases through collaborations with National 
Children’s Hospital (at the time).
(iii) Millennium Genome Project[17]
Period: 2000~2004
Support: The Ministry of Education, Culture, 
Sports, Science and Technology, the Ministry 
of Health, Labor and Welfare, the Ministry of 
Economy, Trade and Industry and the Ministry of 
Agriculture, Forestry and Fisheries (rice genome) 
  This project was set up to improve treatments, to 
make possible tailor-made drugs, and to develop 
new drugs based on the analysis of disease genes. 
The project dealt with structures and functional 
analysis of human full-length cDNAs, SNPs 
analysis and genetic analysis of important diseases. 
(iv) Genome Network Project [18]
Period: 2004~2008
Support: The Ministry of Education, Culture, 
Sports, Science and Technology
  The aim of this project was to develop new 
therapeutic methods and drugs using the information 
obtained to help understanding the network involved 
in vital phenomena, by analyzing the expression 
regulation and function of the genes and the 
interactions among biological molecules. 
5-1-2 Research and Development of Antibody 
Production and Preparation Technology 
   Some projects aim to reduce the costs of expensive 
antibody drugs by improving the ability to produce 
them or by efficiently preparing antibodies against 
various molecules. The followings are some examples. 
(i) Development of Bioprocesses for Practical Use[19]
Period: 2004~2006
Support: The Ministry of Economy, Trade and 
Industry
   This project was not limited to antibodies, but was 
one in which private companies were assisted in the 
research and development of a production system 
for proteins and other chemical agents using various 
hosts, such as silk worms, chickens, animal cells, 
and yeast. 
(ii) Development of New Functional Antibody 
Technologies[20]
Period: 2006~2010
Support: The Ministry of Economy, Trade and 
Industry
   This project is being conducted with the goal to 
develop technology for the production of antigens, 
to systematically prepare highly specific antibodies, 
to develop basic technology to enhance antigen 
presentation and for prevention of immunological 
tolerance, and to promote eff iciency of the 
separation and purification of antibodies. 
5-2 Highly Notable Technologies
(1) Expression of Membrane Proteins Using 
Baculovirus, and Its Use in Antibody Preparation[21]
   As mentioned in 4-3, antibodies against multipass 
transmembrane proteins are usually difficult to 
produce. One of the approaches was to develop a 
method of synthesizing a large amount of membrane 
proteins as antigens with correct three-dimensional 
structure. In this, a method to hyperexpress the target 
membrane protein on viral particles, which are used 
for immunization has been developed. 
   Professor Takao Hamakubo and collaborators 
at the University of Tokyo’s Research Center for 
Advanced Science and Technology have designed 
the target protein to be expressed on the membrane 
of the baculovirus, which infects insects, and 
developed a method to immunize animals with 
these viral particles. Since baculovirus has a highly 
antigenic membrane protein called gp64, direct 
immunization of baculovirus results in obtaining 
mostly antibodies for gp64. Therefore, by inducing an 
immunological tolerance against gp64 in transgenic 
mice engineered to express gp64, antibodies for the 
target membrane protein were successfully obtained. 
Conversely, engineering a knockout mouse with a 
specific GPCR gene (7-transmembrane receptors) 
inactivated, and introducing viral particles that 
hyperexpress this GPCR yielded antibodies against 
the receptors. This means that even though it is hard 
to produce antibodies when the antigen molecules 
of humans and mice have similar sequences, we can 
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produce antibodies against human antigen in mice by 
genetically eliminating the mouse’s antigen molecule. 
This is an achievement accomplished as a result of 
the project for the Development of New Functional 
Antibody Technologies, discussed in 5-1-2 (2).
(2) Creation of Human-Antibody Producing Mice
   Normally, antibodies are first produced in mice, 
but as mentioned in 2-2, since murine antibodies are 
foreign to humans, they are eliminated by the human 
immune system. For this reason, technologies have 
been developed to produce chimeric and humanized 
antibodies. However, since they still contain 
murine components, multiple administrations may 
induce human antibodies which reduce the drug’s 
effectiveness and increase the risk of side effects. A 
research team at Kirin Brewery Co., Ltd. (currently 
Kyowa Hakko Kirin Co., Ltd.) has engineered mice 
that stably retain chromosome fragments containing 
human antibody genes by using artificial chromosome 
technology. Moreover, by crossing-breeding these 
mice with other mice, engineered by the American 
company Medarex, Inc., that retained other parts 
of human antibody genes, they were successful in 
bringing about a new breed of mice that can produce 
all types of human antibodies.[22] Antibodies produced 
this way are called “fully human antibodies” or 
simply “human antibodies,” and since they can be 
used directly for the development of antibody drugs, 
they are being used by many companies in the world 
for ongoing antibody production. Thus, this is an 
important example of a domestically developed 
technology that is also notable as an internationally 
advantageous research result.
(3) Antibody Production Methods that Do Not Use 
Animals
  When target molecules are difficult to produce 
antibodies by the immunological method in mice, 
there have been various efforts to produce antibodies 
through methods that are more artificial, and that do 
not use animals. In many cases, using no animals 
results in cutting down on time and costs. The 
important points when producing practical antibodies 
are how to ensure the quantity and variety of antibody 
genes, how to screen antibodies with high binding 
activity and specificity, and how to produce antibodies 
without antigenecity. Some technologies have been 
put into practical use recently, and are receiving much 
attention. 
(i) Phage Display
   Phage display is a technique wherein a target protein 
is expressed on the membrane of a phage, a type 
of virus that infects bacteria. This method involves 
concentrating and isolating the phage that express 
the most appropriate aimed protein through various 
screening methods. Since the structural design of the 
protein - the gene - is already in the phage particles, 
its genetic sequence can be obtained and modified 
once the phage is isolated. In the case of antibodies, 
this process is done with various sequences of the 
variable region. By binding the phage to an antigen 
on a carrier, a phage with high binding affinity can be 
collected and amplified, and by repeating this process, 
the phage expressing the most appropriate molecule 
can be selected. 
   The method used by Cambridge Antibody 
Technology (currently MedImmune LLC)[23] is to 
prepare the heavy chain and the light chain genes 
from human B cells and to express them on the phage 
membrane as single-chain antibodies fused with 
phage membrane protein. There are over 1011 varieties 
of these combinations. By connecting the obtained 
variable region genes to constant region genes, fully 
human antibodies are synthesized. The previously 
mentioned TNF-α specific antibody adalimumab 
(Humira®) is a fully human antibody synthesized 
through this procedure. 
   In addition, technology used in MorphoSys AG 
in Germany[24] involves the artificial synthesis of 
the entire genetic sequence of CDR (2-2) and the 
surrounding region (framework), and expressing 
it on the phage membrane in the form of Fab. 
Multiple sequences were made using the genetic 
information of human antibodies, and when combined 
appropriately, there are over 15 billion combinations. 
This technology has been licensed to multiple major 
pharmaceutical companies. 
(ii) Use of Chicken B Cell Lines[25]
   Antibody genes of B cells can be diversified 
artificially by treating chicken cell line DT40 cells with 
histone deacetylase inhibitor, trichostatin A. Since 
antibody molecules to be produced are expressed 
on the cell membrane of DT40, cells expressing 
antibodies to specific antigens can be recovered. It 
is expected that by using chickens, an organism that 
is evolutionally distant from mice, antibodies with 
different specificities from those of murine antibodies 
20
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
can be produced, and that this will also speed up the 
process. Research is underway to use this method 
for drug, and thus the humanization process is 
being evaluated. Chiome Bioscience Inc., a venture 
company founded by RIKEN is commercializing this 
technology derived from RIKEN’s research . 
(iii) Use of Human B Cells
   It would be extremely practical if antibodies could 
be produced using human B cells, as the process to 
modify them can be eliminated. Morphotek, Inc.[26], a US 
company has developed a method to make B cells that 
produce antibodies to the target antigen by co-culturing 
T cells, B cells, and fractions of peripheral monocytes 
with target antigen, as well as obtaining B cells that 
produce antibodies against specific antigens by using the 
serum of patients which contains antigens related to those 
diseases. In addition, the technology that selects the 
ideal antibody through the diversification of antibody 
genes, which is accomplished by accumulating 
artificial genetic mutations in B cells, has already 
been developed. Already, multiple antibodies 
produced through this method are undergoing clinical 
trials. This venture company was bought out by 
Eisai Co., Ltd. in 2007. On the other hand Japanese 
venture company, Evec, Inc.[27] has commercialized 
the technology to produce various types of human 
antibodies using human B cells immortalized by 
Epstein-Barr Virus (EBV) based on the technology 
developed at Hokkaido University. 
(4 )  H i g h  A D CC  A nt i b o d y  P r o duc t i o n 
Technology[28]
   The Fc region of antibodies has a sugar chain 
attached, and cytotoxic immunocytes, such as natural 
killer (NK) cells, recognize these regions and attack 
cells such as cancer cells when these antibodies are 
bound (ADCC:2-3-[2]). These sugar chains have 
complex structures; however, it is known that ADCC 
activity is greatly influenced by the presence or 
absence of a specific type of sugar called fucose at 
the base. When fucose is absent, ADCC activity is 
over 100 fold higher compared to when fucose is 
present. Therefore, when the genes for the enzymes 
that attach fucose were knocked out in CHO cells, 
cells often used in antibody production, the antibodies 
produced with these cells had no fucose. Antibodies 
produced by these cells were found to have much 
more higher ADCC activity, and are now being used 
in the development of antibody drugs. This series of 
research projects was done by Kyowa Hakko Co., 
Ltd. (currently Kyowa Hakko Kirin Co., Ltd.), and is 
currently licensed to domestic and foreign companies. 
Additionally, a company overseas has developed the 
technology to improve ADCC activity by modifying 
the amino acid sequence in the Fc region. 
Future Perspectives
  It is a wonderful progress that antibody drugs 
can now save patients who have diseases for which 
previously there was no sufficient treatment. However, 
treatment with antibody drugs is extremely expensive, 
and from a medical economic perspective, the 
evaluation on cost verses effect will be bitter in the 
future. In this sense, it is important to show reliable 
efficacy within the limited field.
   The majority of the companies around the world 
that are developing antibody drugs are bioventure 
companies such as Genentech or Amgen. Most of 
these are companies with the experience of having 
developed protein drugs in the 1980s. Since antibody 
drugs are protein drugs as well, the know-how from 
those developments is seemed to be very useful. 
In Japan, 3 pharmaceutical companies (currently 
2 due to a merger) have been making great efforts 
to develop antibody drugs, and they all have a 
experience of successfully developing protein drugs. 
In 2005, tocilizumab (Actemra), developed by Chugai 
Pharmaceutical Co., Ltd. was launched as the first 
domestically-developed antibody drug.
   On the other hand, most major pharmaceutical 
companies deal with traditional small molecule drugs. 
At the initial stages of antibody drug development, 
it may be a natural choice for them to continue with 
the development of small molecule drugs with their 
established efficacy, rather than taking risks with 
antibody drugs. However, development of small 
molecule drugs was starting to face difficulties as well. 
With the long history of drug development for their 
main targets - diseases that commonly affect adults 
- such as antihypertensive drugs and hyperlipidemia 
drugs, which gave high degree of satisfaction, were 
already on the market, and there was little room 
left for further improvement. At the same time, the 
development of drugs to treat unmet medical needs 
comes with much difficulty as well, and the number 
of new drugs that are approved each year is slowly 
decreasing. Moreover, even the drugs that boast the 
6
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highest sales face great reductions in their sales as 
soon as their patent expires and generic drugs replace 
them. 
   Compared to the very large group of patients of 
lifestyle disease who receive daily administration 
of medications, the patients that could benefit from 
antibody drugs are relatively small in number. 
Traditionally, pharmaceutical companies were not 
aggressive about developing drugs if it seemed 
unlikely to produce big sales. However, due to the 
high prices of antibody drugs as well as their high 
effectiveness within a small disease sector, there were 
5 drugs in the top sale ranking as indicated in Table 
1, marking a double-digit increase in sales compared 
to the previous year. At present it is believed that 
replacing these antibody drugs with generic drugs 
will not be as easy as it was for small molecule drugs. 
For these reasons, major pharmaceutical companies in 
the world are starting to have dealings with antibody 
drugs through merges and partnering. 
   As previously stated, drug development is very 
closely related to basic research in Biology and 
Medicine. In particular, information about target 
molecules and their functions as well as their 
involvement in pathology mostly come from basic 
research conducted in universities and public research 
institutes. In recent years, major pharmaceutical 
companies around the world are reducing the size of 
the departments for basic research and starting to rely 
on venture companies and their sources of knowlege, 
universities, for this information. Antigens which are 
new targets for antibody drugs, antibody itself and the 
next generation of drugs, such as nucleic acid drugs 
and cancer vaccines, are all based on the knowledge 
obtained from basic research, and the public research 
such as that being conducted in universities will be far 
more important in the future. 
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